Plant-derived vascular disrupting agents: Compounds, actions, and clinical trials

Phytochemistry Reviews

Volumn 13, Issue 1, 2014, Pages 191-206

  Kretzschmann, Verena K ^a,b   Fürst, Robert ^b  

^a UNIVERSITY OF MUNICH   (Germany)

^b GOETHE UNIVERSITY   (Germany)

Author keywords

Anti vascular therapy; Cancer; Combretastatin; DMXAA; Tubulin binding drugs

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; COLCHICINE; COMBRETASTATIN A1 PHOSPHATE; COMBRETASTATIN A4; COMBRETASTATIN A4 PHOSPHATE; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; FOLINIC ACID; GEFITINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MELPHALAN; MITOFLAXONE; N ACETYLCOLCHINOL PHOSPHATE; OMBRABULIN; OXALIPLATIN; PACLITAXEL; PLATINUM COMPLEX; TAXANE DERIVATIVE; THALIDOMIDE; TROPONIN I; VADIMEZAN; VANDETANIB; VASCULAR TARGETING AGENT;

ABDOMINAL PAIN; ACUTE CORONARY SYNDROME; ADRENAL CORTEX CARCINOMA; AMINOTRANSFERASE BLOOD LEVEL; ANAPLASTIC THYROID CANCER; ANTIANGIOGENIC ACTIVITY; ANXIETY; ASTHENIA; ASYMPTOMATIC DISEASE; ATAXIA; BLOOD PRESSURE VARIABILITY; BLURRED VISION; BONE MARROW SUPPRESSION; BRAIN ISCHEMIA; BREAST ADENOCARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER PAIN; CANCER RADIOTHERAPY; CARCINOSARCOMA; CASTRATION RESISTANT PROSTATE CANCER; COLON TUMOR; CONFUSION; CONSTIPATION; DEEP VEIN THROMBOSIS; DIPLOPIA; DOSE RESPONSE; DRUG CLEARANCE; DRUG EXPOSURE; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; DYSPNEA; ENDOTHELIUM CELL; ESOPHAGUS FISTULA; FAINTNESS; FATIGUE; HEADACHE; HEART ATRIUM FIBRILLATION; HEART CONDUCTION; HEART DISEASE; HEART EJECTION FRACTION; HEART MUSCLE ISCHEMIA; HEART RATE VARIABILITY; HEART VENTRICLE TACHYCARDIA; HOT FLUSH; HUMAN; HYPERTENSION; HYPOTENSION; HYPOXIA; INFECTION; INTESTINE ISCHEMIA; KIDNEY CARCINOMA; LUNG EMBOLISM; LUNG NON SMALL CELL CANCER; METASTASIS; METASTATIC COLORECTAL CANCER; MONOTHERAPY; MOTOR NEUROPATHY; MULTIPLE CYCLE TREATMENT; NAIL DISEASE; NAUSEA; NEUROPATHY; NEUTROPENIA; NONHUMAN; PAIN; PRIORITY JOURNAL; QT PROLONGATION; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SLURRED SPEECH; SOFT TISSUE SARCOMA; THROMBOPHLEBITIS; TREMOR; TUMOR LYSIS SYNDROME; TUMOR VASCULARIZATION; UNSPECIFIED SIDE EFFECT; URINE INCONTINENCE; VISUAL DISORDER; VOMITING;

EID: 84896705592     PISSN: 15687767     EISSN: 1572980X     Source Type: Journal    
DOI: 10.1007/s11101-013-9304-6     Document Type: Review

References (139)

1. Baguley BC (2003) Antivascular therapy of cancer: DMXAA. Lancet Oncol 4:141-148
2. Baguley BC, Ching LM (1997) Immunomodulatory actions of xanthenone anticancer agents. BioDrugs 8:119-127 (Pubitemid 27316546)
3. Baguley BC, Calveley SB, Crowe KK et al (1989) Comparison of the effects of flavone acetic acid, fostriecin, homoharringtonine and tumour necrosis factor alpha on colon 38 tumours in mice. Eur J Cancer Clin Oncol 25:263-269 (Pubitemid 19054830)
4. Baluk P, Morikawa S, Haskell A et al (2003) Abnormalities of basement membrane on blood vessels and endothelial sprouts in tumors. Am J Pathol 163:1801-1815 (Pubitemid 37310012)
5. Beerepoot LV, Radema SA, Witteveen EO et al (2006) Phase I clinical evaluation of weekly administration of the novel vascular-targeting agent, ZD6126, in patients with solid tumors. J Clin Oncol 24:1491-1498 (Pubitemid 46638769)
6. Blakey DC, Ashton SE, Westwood FR et al (2002a) ZD6126: a novel small molecule vascular targeting agent. Int J Radiat Oncol Biol Phys 54:1497-1502 (Pubitemid 35380055)
7. Blakey DC, Westwood FR, Walker M et al (2002b) Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models. Clin Cancer Res 8:1974-1983 (Pubitemid 34633761)
8. Boucher Y, Baxter LT, Jain RK (1990) Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: implications for therapy. Cancer Res 50:4478-4484 (Pubitemid 20230379)
9. Boyland E, Boyland ME (1937) Studies in tissue metabolism: the action of colchicine and B. typhosus extract. Biochem J 31:454-460
10. Cao Z, Joseph WR, Browne WL et al (1999) Thalidomide increases both intra-tumoural tumour necrosis factor-alpha production and anti-tumour activity in response to 5,6-dimethylxanthenone-4-acetic acid. Br J Cancer 80:716-723 (Pubitemid 29209834)
11. Carmeliet P, Jain RK (2000) Angiogenesis in cancer and other diseases. Nature 407:249-257
12. Chaplin DJ, Hill SA (2002) The development of combretastatin A4 phosphate as a vascular targeting agent. Int J Radiat Oncol Biol Phys 54:1491-1496 (Pubitemid 35380054)
13. Chaplin DJ, Pettit GR, Hill SA (1999) Anti-vascular approaches to solid tumour therapy: evaluation of combretastatin A4 phosphate. Anticancer Res 19:189-195 (Pubitemid 29168237)
14. Ching LM, Joseph WR, Crosier KE et al (1994) Induction of tumor necrosis factor-alpha messenger RNA in human and murine cells by the flavone acetic acid analogue 5,6-dimethylxanthenone-4-acetic acid (NSC 640488). Cancer Res 54:870-872 (Pubitemid 24085430)
15. Ching LM, Cao Z, Kieda C et al (2002) Induction of endothelial cell apoptosis by the antivascular agent 5,6-Dimethylxanthenone-4-acetic acid. Br J Cancer 86:1937-1942
16. Ching LM, Zwain S, Baguley BC (2004) Relationship between tumour endothelial cell apoptosis and tumour blood flow shutdown following treatment with the antivascular agent DMXAA in mice. Br J Cancer 90:906-910 (Pubitemid 38406605)
17. Cook KM, Figg WD (2010) Angiogenesis inhibitors: current strategies and future prospects. CA Cancer J Clin 60:222-243
18. Cooney MM, van Heeckeren W, Bhakta S et al (2006) Drug insight: vascular disrupting agents and angiogenesis-novel approaches for drug delivery. Nat Clin Pract Oncol 3:682-692 (Pubitemid 44843126)
19. Corbett TH, Bissery MC, Wozniak A et al (1986) Activity of flavone acetic acid (NSC-347512) against solid tumors of mice. Invest New Drugs 4:207-220 (Pubitemid 17205949)
20. Dark GG, Hill SA, Prise VE et al (1997) Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res 57:1829-1834 (Pubitemid 27209705)
21. Davis PD, Dougherty GJ, Blakey DC et al (2002) ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculature. Cancer Res 62:7247-7253 (Pubitemid 36025246)
22. Delmonte A, Sessa C (2009) AVE8062: a new combretastatin derivative vascular disrupting agent. Exp Opin Invest Drugs 18:1541-1548
23. DelProposto Z, LoRusso P, Latif Z et al (2002) MRI evaluation of the effects of the vascular-targeting agent ZD6126 on tumor vasculature. Proc Am Soc Clin Oncol 21:abstr 440
24. Demers B, Vrignaud P, Bissery M (2006) In vivo synergy combining oxaliplatin with AVE8062, a vascular-disrupting agent. J Clin Oncol 24:607s abstract 13074
25. Denekamp J (1982) Endothelial cell proliferation as a novel approach to targeting tumour therapy. Br J Cancer 45:136-139
26. Denekamp J (1999) The tumour microcirculation as a target in cancer therapy: a clearer perspective. Eur J Clin Invest 29:733-736
27. Dowlati A, Robertson K, Cooney M et al (2002) A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res 62:3408-3416 (Pubitemid 34651387)
28. Dumontet C, Jordan MA (2010) Microtubule-binding agents: a dynamic field of cancer therapeutics. Nat Rev Drug Discov 9:790-803
29. Dvorak HF, Nagy JA, Dvorak JT et al (1988) Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. Am J Pathol 133:95-109
30. Evelhoch JL, LoRusso PM, He Z et al (2004) Magnetic resonance imaging measurements of the response of murine and human tumors to the vascular-targeting agent ZD6126. Clin Cancer Res 10:3650-3657 (Pubitemid 38697598)
31. Fox SB, Gatter KC, Bicknell R et al (1993) Relationship of endothelial cell proliferation to tumor vascularity in human breast cancer. Cancer Res 53:4161-4163 (Pubitemid 24146759)
32. Gadgeel SM, LoRusso PM, Wozniak AJ et al (2002) A dose-escalation study of the novel vascular-targeting agent, ZD6126, in patients with solid tumors. Proc Am Soc Clin Oncol 21:abstr 438
33. Galbraith SM, Chaplin DJ, Lee F et al (2001) Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo. Anticancer Res 21:93-102 (Pubitemid 32267629)
34. Galbraith SM, Rustin GJ, Lodge MA et al (2002) Effects of 5,6-dimethylxanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging. J Clin Oncol 20:3826-3840
35. Goertz DE, Yu JL, Kerbel RS et al (2002) High-frequency Doppler ultrasound monitors the effects of antivascular therapy on tumor blood flow. Cancer Res 62:6371-6375 (Pubitemid 35364088)
36. Grosios K, Loadman PM, Swaine DJ et al (2000) Combination chemotherapy with combretastatin A-4 phosphate and 5-fluorouracil in an experimental murine colon adenocarcinoma. Anticancer Res 20:229-233 (Pubitemid 30189759)
37. Hanahan D, Folkman J (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86:353-364 (Pubitemid 26272076)
38. Hashizume H, Baluk P, Morikawa S et al (2000) Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol 156:1363-1380 (Pubitemid 30660013)
39. Hill SA, Chaplin DJ, Lewis G et al (2002a) Schedule dependence of combretastatin A4 phosphate in transplanted and spontaneous tumour models. Int J Cancer 102:70-74
40. Hill SA, Toze GM, Pettit GR et al (2002b) Preclinical evaluation of the antitumour activity of the novel vascular targeting agent Oxi 4503. Anticancer Res 22:1453-1458 (Pubitemid 34839149)
41. Hoang T, Huang S, Armstrong E et al (2006) Augmentation of radiation response with the vascular targeting agent ZD6126. Int J Radiat Oncol Biol Phys 64:1458-1465
42. Hobbs SK, Monsky WL, Yuan F et al (1998) Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci USA 95:4607-4612 (Pubitemid 28207960)
43. Hokland SL, Horsman MR (2007) The new vascular disrupting agent combretastatin-A1-disodium-phosphate (OXi4503) enhances tumour response to mild hyperthermia and thermoradiosensitization. Int J Hyperth 23:599-606 (Pubitemid 350187055)
44. Hollebecque A, Massard C, Soria JC (2012) Vascular disrupting agents: a delicate balance between efficacy and side effects. Curr Opin Oncol 24:305-315
45. Holwell SE, Cooper PA, Grosios K et al (2002a) Combretastatin A-1 phosphate a novel tubulin-binding agent with in vivo anti vascular effects in experimental tumours. Anticancer Res 22:707-711 (Pubitemid 34475218)
46. Holwell SE, Cooper PA, Thompson MJ et al (2002b) Anti-tumor and anti-vascular effects of the novel tubulin-binding agent combretastatin A-1 phosphate. Anticancer Res 22:3933-3940 (Pubitemid 36134416)
47. Hori K, Saito S (2003) Microvascular mechanisms by which the combretastatin A-4 derivative AC7700 (AVE8062) induces tumour blood flow stasis. Br J Cancer 89:1334-1344 (Pubitemid 37363426)
48. Hori K, Saito S, Nihei Y et al (1999) Antitumor effects due to irreversible stoppage of tumor tissue blood flow: evaluation of a novel combretastatin A-4 derivative, AC7700. Jpn J Cancer Res 90:1026-1038 (Pubitemid 29500444)
49. Hori K, Saito S, Sato Y et al (2003) Differential relationship between changes in tumour size and microcirculatory functions induced by therapy with an antivascular drug and with cytotoxic drugs. implications for the evaluation of therapeutic efficacy of AC7700 (AVE8062). Eur J Cancer 39:1957-1966 (Pubitemid 37311194)
50. Horsman MR, Murata R (2002) Combination of vascular targeting agents with thermal or radiation therapy. Int J Radiat Oncol Biol Phys 54:1518-1523 (Pubitemid 35380058)
51. Horsman MR, Ehrnrooth E, Ladekarl M et al (1998) The effect of combretastatin A-4 disodium phosphate in a C3H mouse mammary carcinoma and a variety of murine spontaneous tumors. Int J Radiat Oncol Biol Phys 42:895-898 (Pubitemid 28559438)
52. Horsman MR, Murata R, Breidahl T et al (2000) Combretastatins novel vascular targeting drugs for improving anticancer therapy. Combretastatins and conventional therapy. Adv Exp Med Biol 476:311-323 (Pubitemid 32176147)
53. Iyer S, Chaplin DJ, Rosenthal DS et al (1998) Induction of apoptosis in proliferating human endothelial cells by the tumor-specific antiangiogenesis agent combretastatin A-4. Cancer Res 58:4510-4514 (Pubitemid 28480604)
54. Jameson MB, Thompson PI, Baguley BC et al (2003) Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent. Br J Cancer 88:1844-1850 (Pubitemid 36829657)
55. Kang GJ, Getahun Z, Muzaffar A et al (1990) N-acetylcolchinol O-methyl ether and thiocolchicine, potent analogs of colchicine modified in the C ring. Evaluation of the mechanistic basis for their enhanced biological properties. J Biol Chem 265:10255-10259
56. Kanthou C, Tozer GM (2002) The tumor vascular targeting agent combretastatin A-4-phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing in human endothelial cells. Blood 99:2060-2069 (Pubitemid 34525489)
57. Karin M, Ben-Neriah Y (2000) Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu Rev Immunol 18:621-663 (Pubitemid 30365393)
58. Ke Q, Bodyak N, Rigor DL et al (2009) Pharmacological inhibition of the hypertensive response to combretastatin A-4 phosphate in rats. Vascul Pharmacol 51:337-343
59. Kerr DJ, Maughan T, Newlands E et al (1989) Phase II trials of flavone acetic acid in advanced malignant melanoma and colorectal carcinoma. Br J Cancer 60:104-106 (Pubitemid 19188740)
60. Kim TJ, Ravoori M, Landen CN et al (2007) Antitumor and antivascular effects of AVE8062 in ovarian carcinoma. Cancer Res 67:9337-9345 (Pubitemid 47535923)
61. Kirwan IG, Loadman PM, Swaine DJ et al (2004) Comparative preclinical pharmacokinetic and metabolic studies of the combretastatin prodrugs combretastatin A4 phosphate and A1 phosphate. Clin Cancer Res 10:1446-1453 (Pubitemid 38365240)
62. Kobayashi H, Tsuruchi N, Sugihara K et al (1993) Expression of alpha-smooth muscle actin in benign or malignant ovarian tumors. Gynecol Oncol 48:308-313 (Pubitemid 23090797)
63. Krendel M, Zenke FT, Bokoch GM(2002) Nucleotide exchange factor GEF-H1 mediates cross-talk between microtubules and the actin cytoskeleton. Nat Cell Biol 4:294-301 (Pubitemid 34308855)
64. Landuyt W, Verdoes O, Darius DO et al (2000) Vascular targeting of solid tumours: a major 'inverse' volume-response relationship following combretastatin A-4 phosphate treatment of rat rhabdomyosarcomas. Eur J Cancer 36:1833-1843 (Pubitemid 30639504)
65. Lara PN Jr, Douillard JY, Nakagawa K et al (2011) Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer. J Clin Oncol 29:2965-2971
66. Lash CJ, Li AE, Rutland M et al (1998) Enhancement of the anti-tumour effects of the antivascular agent 5,6-dime-thylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs. Br J Cancer 78:439-445 (Pubitemid 28360629)
67. Lejeune P, Vrignaud P, Goulaouic H et al (2005) In vivo synergy between docetaxel and AVE8062A, a tumor vasculature targeting agent. AACR Meet Abstr 46:807-808
68. Lin CM, Singh SB, Chu PS et al (1988) Interactions of tubulin with potent natural and synthetic analogs of the antimitotic agent combretastatin: a structure-activity study. Mol Pharmacol 34:200-208
69. Lin CM, Ho HH, Pettit GR et al (1989) Antimitotic natural products combretastatin A-4 and combretastatin A-2: studies on the mechanism of their inhibition of the binding of colchicine to tubulin. Biochemistry 28:6984-6991 (Pubitemid 19219888)
70. Lin PS, Ho KC, Sung SJ et al (1992) Effect of tumour necrosis factor, heat, and radiation on the viability and microfilament organization in cultured endothelial cells. Int J Hyperth 8:667-677
71. Lippert JW 3rd (2007) Vascular disrupting agents. Bioorg Med Chem 15:605-615
72. LoRusso PM, Gadgeel SM, Wozniak A et al (2008) Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid tumors. Invest New Drugs 26:159-167
73. Ludford RJ (1948) Factors determining the action of colchicine on tumour growth. Br J Cancer 2:75-86
74. Martinelli M, Bonezzi K, Riccardi E et al (2007) Sequence dependent antitumour efficacy of the vascular disrupting agent ZD6126 in combination with paclitaxel. Br J Cancer 97:888-894 (Pubitemid 47519312)
75. McKeage MJ, Fong P, Jeffery M et al (2006) 5,6-Dimethylxanthenone-4- acetic acid in the treatment of refractory tumors: a phase I safety study of a vascular disrupting agent. Clin Cancer Res 12:1776-1784
76. McKeage MJ, Von Pawel J, Reck M et al (2008) Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. Br J Cancer 99:2006-2012
77. McKeage MJ, Reck M, Jameson MB et al (2009) Phase II study of ASA404 (vadimezan, 5,6-dimethylxanthenone-4-acetic acid/DMXAA) 1800 mg/m(2) combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. Lung Cancer 65:192-197
78. Meyer T, Gaya AM, Dancey G et al (2009) A phase I trial of radioimmunotherapy with 131I-A5B7 anti-CEA antibody in combination with combretastatin-A4-phosphate in advanced gastrointestinal carcinomas. Clin Cancer Res 15:4484-4492
79. Micheletti G, Poli M, Borsotti P et al (2003) Vascular-targeting activity of ZD6126, a novel tubulin-binding agent. Cancer Res 63:1534-1537 (Pubitemid 36373640)
80. Mooney CJ, Nagaiah G, Fu P et al (2009) A phase II trial of fosbretabulin in advanced anaplastic thyroid carcinoma and correlation of baseline serum-soluble intracellular adhesion molecule-1 with outcome. Thyroid 19:233-240
81. Murata R, Overgaard J, Horsman MR (2001a) Combretastatin A-4 disodium phosphate: a vascular targeting agent that improves that improves the anti-tumor effects of hyperthermia, radiation, and mild thermoradiotherapy. Int J Radiat Oncol Biol Phys 51:1018-1024 (Pubitemid 33026433)
82. Murata R, Overgaard J, Horsman MR (2001b) Comparative effects of combretastatin A-4 disodium phosphate and 5,6-dimethylxanthenone-4-acetic acid on blood perfusion in a murine tumour and normal tissues. Int J Radiat Biol 77:195-204 (Pubitemid 32158366)
83. Murata R, Siemann DW, Overgaard J et al (2001c) Interaction between combretastatin A-4 disodium phosphate and radiation in murine tumors. Radiother Oncol 60:155-161 (Pubitemid 32601968)
84. Nathan P, Zweifel M, Padhani AR et al (2012) Phase I trial of combretastatin A4 phosphate (CA4P) in combination with bevacizumab in patients with advanced cancer. Clin Cancer Res 18:3428-3439
85. Nelkin BD, Ball DW (2001) Combretastatin A-4 and doxorubicin combination treatment is effective in a preclinical model of human medullary thyroid carcinoma. Oncol Rep 8:157-160 (Pubitemid 33758220)
86. Ng QS, Mandeville H, Goh V et al (2012) Phase Ib trial of radiotherapy in combination with combretastatin-A4-phosphate in patients with non-small-cell lung cancer, prostate adenocarcinoma, and squamous cell carcinoma of the head and neck. Ann Oncol 23:231-237
87. Nihei Y, Suga Y, Morinaga Y et al (1999a) A novel combretastatin A-4 derivative, AC-7700, shows marked antitumor activity against advanced solid tumors and orthotopically transplanted tumors. Jpn J Cancer Res 90:1016-1025 (Pubitemid 29500443)
88. Nihei Y, Suzuki M, Okano A et al (1999b) Evaluation of antivascular and antimitotic effects of tubulin binding agents in solid tumor therapy. Jpn J Cancer Res 90:1387-1395 (Pubitemid 30032079)
89. Ohsumi K, Nakagawa R, Fukuda Y et al (1998) Novel combretastatin analogues effective against murine solid tumors: design and structure-activity relationships. J Med Chem 41:3022-3032 (Pubitemid 28359938)
90. Patterson DM, Zweifel M, Middleton MR et al (2012) Phase I clinical and pharmacokinetic evaluation of the vascular-disrupting agent OXi4503 in patients with advanced solid tumors. Clin Cancer Res 18:1415-1425
91. Pedley RB, Boden JA, Boden R et al (1996) Ablation of colorectal xenografts with combined radioimmunotherapy and tumor blood flow-modifying agents. Cancer Res 56:3293-3300 (Pubitemid 26242979)
92. Pedley RB, Hill SA, Boxer GM et al (2001) Eradication of colorectal xenografts by combined radioimmunotherapy and combretastatin a-4 3-O-phosphate. Cancer Res 61:4716-4722 (Pubitemid 32691881)
93. Pettit GR, Lippert JW 3rd (2000) Antineoplastic agents 429. Syntheses of the combretastatin A-1 and combretastatin B-1 prodrugs. Anticancer Drug Des 15:203-216
94. Pettit GR, Singh SB, Niven ML et al (1987) Isolation, structure, and synthesis of combretastatins A-1 and B-1, potent new inhibitors of microtubule assembly, derived from Combretum caffrum. J Nat Prod 50:119-131
95. Pettit GR, Singh SB, Hamel E et al (1989) Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4. Experientia 45:209-211 (Pubitemid 19062390)
96. Pettit GR, Temple C Jr, Narayanan VL et al (1995) Antineoplastic agents 322. synthesis of combretastatin A-4 prodrugs. Anticancer Drug Des 10:299-309
97. Philpott M, Baguley BC, Ching LM (1995) Induction of tumour necrosis factor-alpha by single and repeated doses of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid. Cancer Chemother Pharmacol 36:143-148
98. Philpott M, Ching LM, Baguley BC (2001) The antitumour agent 5,6-dimethylxanthenone-4-acetic acid acts in vitro on human mononuclear cells as a co-stimulator with other inducers of tumour necrosis factor. Eur J Cancer 37:1930-1937 (Pubitemid 32913322)
99. Pilat MJ, Lorusso PM (2006) Vascular disrupting agents. J Cell Biochem 99:1021-1039 (Pubitemid 44673961)
100. Pili R, Rosenthal MA, Mainwaring PN et al (2010) Phase II study on the addition of ASA404 (vadimezan; 5,6-dime-thylxanthenone-4-acetic acid) to docetaxel in CRMPC. Clin Cancer Res 16:2906-2914
101. Pruijn FB, van Daalen M, Holford NH et al (1997) Mechanisms of enhancement of the antitumour activity of melphalan by the tumour-blood-flow inhibitor 5,6-dimethylxanthenone-4-acetic acid. Cancer Chemother Pharmacol 39:541-546 (Pubitemid 27096771)
102. Raben D, Bianco C, Damiano V et al (2004) Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft model. Mol Cancer Ther 3:977-983 (Pubitemid 39199592)
103. Rewcastle GW, Atwell GJ, Baguley BC et al (1991) Potential antitumor agents. 63. Structure-activity relationships for side-chain analogues of the colon 38 active agent 9-oxo-9H-xanthene-4-acetic acid. J Med Chem 34:2864-2870
104. Risau W (1997) Mechanisms of angiogenesis. Nature 386:671-674
105. Rustin GJ, Galbraith SM, Anderson H et al (2003) Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results. J Clin Oncol 21:2815-2822 (Pubitemid 46621828)
106. Rustin GJ, Shreeves G, Nathan PD et al (2010) A Phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer. Br J Cancer 102:1355-1360
107. Salmon HW, Siemann DW (2006) Effect of the second-generation vascular disrupting agent OXi4503 on tumor vascularity. Clin Cancer Res 12:4090-4094 (Pubitemid 44078097)
108. Seed L, Slaughter DP, Limarzi LR (1940) Effect of colchicine on human carcinoma. Surgery 7:696-709
109. Seshadri M, Spernyak JA, Mazurchuk R et al (2005) Tumor vascular response to photodynamic therapy and the antivascular agent 5,6-dimethylxanthenone-4- acetic acid: implications for combination therapy. Clin Cancer Res 11:4241-4250 (Pubitemid 40791591)
110. Sessa C, Lorusso P, Tolcher AW et al (2005) A pharmacokinetic and DCE-MRI-dynamic Phase I study of the antivascular combretastatin analogue AVE8062A administered every 3 weeks. AACR Meet Abstr 46:1371
111. Sessa C, Soria JC, Tolcher AW et al (2009) A phase I pharmacokinetic and pharmacodynamic study of AVE8062 in patients with advanced solid tumors. Ann Oncol 20(Suppl 3):iii24
112. Shi W, Siemann DW (2005) Targeting the tumor vasculature: enhancing antitumor efficacy through combination treatment with ZD6126 and ZD6474. In Vivo 19:1045-1050 (Pubitemid 41631508)
113. Shnyder SD, Cooper PA, Pettit GR et al (2003) Combretastatin A-1 phosphate potentiates the antitumour activity of cisplatin in a murine adenocarcinoma model. Anticancer Res 23:1619-1623 (Pubitemid 36754137)
114. Siemann DW (2011) The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting Agents. Cancer Treat Rev 37:63-74
115. Siemann DW, Rojiani AM (2002a) Antitumor efficacy of conventional anticancer drugs is enhanced by the vascular targeting agent ZD6126. Int J Radiat Oncol Biol Phys 54:1512-1517 (Pubitemid 35380057)
116. Siemann DW, Rojiani AM (2002b) Enhancement of radiation therapy by the novel vascular targeting agent ZD6126. Int J Radiat Oncol Biol Phys 53:164-171 (Pubitemid 34465821)
117. Siemann DW, Shi W (2004) Efficacy of combined antiangiogenic and vascular disrupting agents in treatment of solid tumors. Int J Radiat Oncol Biol Phys 60:1233-1240 (Pubitemid 39440810)
118. Siemann DW, Shi W (2008) Dual targeting of tumor vasculature: combining Avastin and vascular disrupting agents (CA4P or OXi4503). Anticancer Res 28:2027-2031
119. Siemann DW, Mercer E, Lepler S et al (2002) Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy. Int J Cancer 99:1-6 (Pubitemid 34273190)
120. Siemann DW, Bibby MC, Dark GG et al (2005) Differentiation and definition of vascular-targeted therapies. Clin Cancer Res 11:416-420 (Pubitemid 40116863)
121. Siemann DW, Chaplin DJ, Walicke PA (2009) A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P). Exp Opin Invest Drugs 18:189-197
122. Siim BG, Lee AE, Shalal-Zwain S et al (2003) Marked potentiation of the antitumour activity of chemotherapeutic drugs by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Cancer Chemother Pharmacol 51:43-52 (Pubitemid 36057022)
123. Soria J-C, Sessa C, Perotti A et al (2008) A comprehensive study of translational research and safety exploration of the vascular disrupting agent (VDA) AVE8062 in combination with cisplatin administered every 3 weeks to patients with advanced solid tumors. AACR Meet Abstr:LB-302
124. Sosa JA, Elisei R, Jarzab B et al (2011) A randomized phase II/III trial of a tumor vascular disrupting agent fosbretabulin tromethamine (CA4P) with carboplatin (C) and paclitaxel (P) in anaplastic thyroid cancer (ATC): Final survival analysis for the FACT trial. J Clin Oncol 29:suppl, abstr 5502
125. Stevenson JP, Rosen M, Sun W et al (2003) Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow. J Clin Oncol 21:4428-4438 (Pubitemid 46621821)
126. Thorpe PE (2004) Vascular targeting agents as cancer therapeutics. Clin Cancer Res 10:415-427
127. Tolcher AW, Forero L, Celio P et al (2003) Phase I, pharmacokinetic, and DCE-MRI correlative study of AVE8062A, an antivascular combretastatin analogue, administered weekly for 3 weeks every 28-days Proc Am Soc Clin Oncol 22:abstr 834
128. Tozer GM, Lewis S, Michalowski A et al (1990) The relationship between regional variations in blood flow and histology in a transplanted rat fibrosarcoma. Br J Cancer 61:250-257 (Pubitemid 20058284)
129. Tozer GM, Prise VE, Wilson J et al (1999) Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues. Cancer Res 59:1626-1634 (Pubitemid 29160136)
130. Tozer GM, Prise VE, Wilson J et al (2001) Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability. Cancer Res 61:6413-6422 (Pubitemid 32785286)
131. Tozer GM, Kanthou C, Parkins CS et al (2002) The biology of the combretastatins as tumour vascular targeting agents. Int J Exp Pathol 83:21-38 (Pubitemid 34638944)
132. Tozer GM, Kanthou C, Baguley BC (2005) Disrupting tumour blood vessels. Nat Rev Cancer 5:423-435 (Pubitemid 40791485)
133. Tresca P, Tosi D, van Doorn L et al (2010) Phase I and pharmacologic study of the vascular disrupting agent ombrabulin (Ob) combined with docetaxel (D) in patients (pts) with advanced solid tumors. J Clin Oncol 28 (suppl abstr 3023)
134. Vincent L, Kermani P, Young LM et al (2005) Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling. J Clin Invest 115:2992-3006 (Pubitemid 41567565)
135. Wachsberger PR, Burd R, Marero N et al (2005) Effect of the tumor vascular-damaging agent, ZD6126, on the radioresponse of U87 glioblastoma. Clin Cancer Res 11:835-842 (Pubitemid 40116912)
136. Wilson WR, Li AE, Cowan DS et al (1998) Enhancement of tumor radiation response by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid. Int J Radiat Oncol Biol Phys 42:905-908 (Pubitemid 28559440)
137. Zhao L, Ching LM, Kestell P et al (2002) The antitumour activity of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF receptor-1 knockout mice. Br J Cancer 87:465-470 (Pubitemid 34983572)
138. Zhao L, Ching LM, Kestell P et al (2005) Mechanisms of tumor vascular shutdown induced by 5,6-dimethylxanthenone-4-acetic acid (DMXAA): increased tumor vascular permeability. Int J Cancer 116:322-326 (Pubitemid 40967272)
139. Zwi LJ, Baguley BC, Gavin JB et al (1994) The morphological effects of the anti-tumor agents flavone acetic acid and 5,6-dimethyl xanthenone acetic acid on the colon 38 mouse tumor. Pathology 26:161-169